Neoadjuvant therapy for melanoma: is it ready for prime time?
Mené sur 35 patients atteints d'un mélanome résécable de stade IIIC-C présentant la mutation V600 du gène BRAF, cet essai de phase II évalue l'efficacité, du point de vue de la proportion de patients obtenant une réponse pathologique complète et de la proportion de patients obtenant une réponse en semaine 12, et la toxicité d'un traitement néoadjuvant combinant dabrafénib et tramétinib (durée médiane de suivi : 27 mois)
In the past, advanced melanoma with nodal or distant metastases was almost universally fatal, with a median overall survival of less than 1 year with few effective therapies. However, with the advent of treatment with immune checkpoint blockade and BRAF-targeted therapy, among other strategies, a dramatic improvement has been seen in the survival of patients with stage IV disease, substantiating approval of such regimens for patients with metastatic melanoma. BRAF-targeted therapy and immune checkpoint inhibitors have also shown efficacy in the adjuvant setting, with approval of these drugs for adjuvant use after surgical resection in the setting of high-risk disease
The Lancet Oncology 2019